Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Carbohydr Polym ; 272: 118461, 2021 Nov 15.
Artigo em Inglês | MEDLINE | ID: mdl-34420721

RESUMO

The molecular weight (Mw) of dextran derivatives, such as regioselectively oxidized dicarboxydextran (DXA), is greatly influencing their faith in an organism, which could be possibly used to improve anticancer drug delivery. Here we present a modified method of sulfonation-induced chain scission allowing direct and accurate control over the Mw of DXA without increasing its polydispersity. Prepared DXA derivatives (Mw = 10-185 kDa) have been conjugated to cisplatin and the Mw of the carrier found to have a significant impact on cisplatin release rates, in vitro cytotoxicity, and migrastatic potential. Conjugates with the high-Mw DXA showed particularly increased anticancer efficacy. The best conjugate was four times more effective against malignant prostatic cell lines than free cisplatin and significantly inhibited the ovarian cancer cell migration. This was traced to the characteristics of spontaneously formed cisplatin-crosslinked DXA nanogels influenced by Mw of DXA and amount of loaded cisplatin.


Assuntos
Antineoplásicos/farmacologia , Cisplatino/farmacologia , Dextranos/química , Portadores de Fármacos/química , Neoplasias/tratamento farmacológico , Células A549 , Adenocarcinoma/tratamento farmacológico , Adenocarcinoma/metabolismo , Antineoplásicos/química , Movimento Celular/efeitos dos fármacos , Cisplatino/química , Sistemas de Liberação de Medicamentos/métodos , Feminino , Humanos , Masculino , Peso Molecular , Nanogéis/química , Neoplasias/metabolismo , Neoplasias Ovarianas/tratamento farmacológico , Neoplasias Ovarianas/metabolismo , Oxirredução , Neoplasias da Próstata/tratamento farmacológico , Neoplasias da Próstata/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...